Artivion strengthens aortic arch portfolio with $135m Endospan acquisition

Artivion has completed a $135 million acquisition of Endospan following US regulatory approval of Nexus, an endovascular device for aortic arch syndrome treatment. The deal, structured under a 2019 agreement, expands Artivion's portfolio in the aortic intervention space and adds Endospan's technology platform to its surgical and interventional cardiology offerings.